IL110566A - Stable aqueous solution of hybrid alpha-interferon - Google Patents
Stable aqueous solution of hybrid alpha-interferonInfo
- Publication number
- IL110566A IL110566A IL11056694A IL11056694A IL110566A IL 110566 A IL110566 A IL 110566A IL 11056694 A IL11056694 A IL 11056694A IL 11056694 A IL11056694 A IL 11056694A IL 110566 A IL110566 A IL 110566A
- Authority
- IL
- Israel
- Prior art keywords
- interferon
- aqueous solution
- stable aqueous
- hybrid alpha
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939316849A GB9316849D0 (en) | 1993-08-13 | 1993-08-13 | Pharmaceutical compositions |
GB9405879A GB9405879D0 (en) | 1994-03-24 | 1994-03-24 | Pharmaceutical compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
IL110566A0 IL110566A0 (en) | 1995-01-24 |
IL110566A true IL110566A (en) | 1999-12-22 |
Family
ID=26303371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11056694A IL110566A (en) | 1993-08-13 | 1994-08-04 | Stable aqueous solution of hybrid alpha-interferon |
Country Status (19)
Country | Link |
---|---|
US (1) | US5609868A (da) |
EP (1) | EP0641567B1 (da) |
JP (1) | JP3745395B2 (da) |
KR (1) | KR100351495B1 (da) |
AT (1) | ATE190498T1 (da) |
AU (1) | AU679233B2 (da) |
CA (1) | CA2129921C (da) |
CY (1) | CY2230B1 (da) |
DE (1) | DE69423402T2 (da) |
DK (1) | DK0641567T3 (da) |
ES (1) | ES2144034T3 (da) |
FI (1) | FI111222B (da) |
GR (1) | GR3033239T3 (da) |
HU (1) | HU224613B1 (da) |
IL (1) | IL110566A (da) |
NO (1) | NO315843B1 (da) |
NZ (1) | NZ264218A (da) |
PT (1) | PT641567E (da) |
TW (1) | TW249202B (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020102236A1 (en) * | 1994-12-08 | 2002-08-01 | Taylor Peter William | Liposomal interferon hybrid compositions |
US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
EE04266B1 (et) * | 1996-12-24 | 2004-04-15 | Biogen, Incorporated | Interferooni stabiilne vedelkompositsioon |
KR19990075253A (ko) * | 1998-03-18 | 1999-10-15 | 성재갑 | 약학적으로 안정한 인터페론 제 |
US6685933B1 (en) | 1998-07-28 | 2004-02-03 | The United States Of America As Represented By The Department Of Health And Human Services | Interferon α hybrids |
ES2167189B1 (es) | 1999-12-17 | 2003-04-01 | Lipotec Sa | Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos |
PT1343518E (pt) | 2000-11-07 | 2009-08-03 | Novartis Vaccines & Diagnostic | Composições de interferão estabilizadas |
US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
AR044302A1 (es) * | 2003-05-13 | 2005-09-07 | Ares Trading Sa | Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos |
CN101304758B (zh) * | 2005-06-29 | 2013-08-21 | 维兹曼科学研究所耶达研究与发展有限公司 | 重组干扰素α2(IFNα2)突变体 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59196823A (ja) * | 1983-04-20 | 1984-11-08 | Sunstar Inc | 皮膚および粘膜の真菌症治療用外用剤 |
US4855238A (en) * | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
GR860758B (en) * | 1985-03-25 | 1986-07-21 | Schering Corp | Stable gamma - interferon formulation |
US4885166A (en) * | 1985-06-11 | 1989-12-05 | Ciba-Geigy Corporation | Hybrid interferons |
US4847079A (en) * | 1985-07-29 | 1989-07-11 | Schering Corporation | Biologically stable interferon compositions comprising thimerosal |
IL88233A (en) * | 1987-11-03 | 1993-08-18 | Genentech Inc | Gamma interferon formulation |
EP0331635A3 (en) * | 1988-02-29 | 1990-02-28 | The Board of Regents of the University of Texas System | Preparations for treating bladder cancer |
-
1994
- 1994-07-18 TW TW083106518A patent/TW249202B/zh active
- 1994-08-04 IL IL11056694A patent/IL110566A/xx not_active IP Right Cessation
- 1994-08-05 AU AU68939/94A patent/AU679233B2/en not_active Ceased
- 1994-08-05 JP JP18465494A patent/JP3745395B2/ja not_active Expired - Fee Related
- 1994-08-10 ES ES94305930T patent/ES2144034T3/es not_active Expired - Lifetime
- 1994-08-10 DE DE69423402T patent/DE69423402T2/de not_active Expired - Fee Related
- 1994-08-10 EP EP94305930A patent/EP0641567B1/en not_active Expired - Lifetime
- 1994-08-10 US US08/288,671 patent/US5609868A/en not_active Expired - Lifetime
- 1994-08-10 FI FI943705A patent/FI111222B/fi active
- 1994-08-10 PT PT94305930T patent/PT641567E/pt unknown
- 1994-08-10 AT AT94305930T patent/ATE190498T1/de not_active IP Right Cessation
- 1994-08-10 DK DK94305930T patent/DK0641567T3/da active
- 1994-08-11 NZ NZ264218A patent/NZ264218A/en not_active IP Right Cessation
- 1994-08-11 CA CA002129921A patent/CA2129921C/en not_active Expired - Fee Related
- 1994-08-12 NO NO19942983A patent/NO315843B1/no not_active IP Right Cessation
- 1994-08-12 KR KR1019940019883A patent/KR100351495B1/ko not_active IP Right Cessation
- 1994-08-12 HU HU9402356A patent/HU224613B1/hu not_active IP Right Cessation
-
2000
- 2000-04-14 GR GR20000400921T patent/GR3033239T3/el not_active IP Right Cessation
-
2001
- 2001-07-30 CY CY0100020A patent/CY2230B1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HU9402356D0 (en) | 1994-10-28 |
ES2144034T3 (es) | 2000-06-01 |
JPH07145070A (ja) | 1995-06-06 |
TW249202B (da) | 1995-06-11 |
HUT68692A (en) | 1995-07-28 |
EP0641567B1 (en) | 2000-03-15 |
DE69423402D1 (de) | 2000-04-20 |
US5609868A (en) | 1997-03-11 |
CA2129921C (en) | 2006-12-05 |
CY2230B1 (en) | 2003-04-18 |
KR950005325A (ko) | 1995-03-20 |
NO942983D0 (no) | 1994-08-12 |
AU6893994A (en) | 1995-02-23 |
FI111222B (fi) | 2003-06-30 |
FI943705A (fi) | 1995-02-14 |
GR3033239T3 (en) | 2000-09-29 |
DE69423402T2 (de) | 2000-08-03 |
CA2129921A1 (en) | 1995-02-14 |
IL110566A0 (en) | 1995-01-24 |
ATE190498T1 (de) | 2000-04-15 |
PT641567E (pt) | 2000-08-31 |
KR100351495B1 (ko) | 2003-02-19 |
EP0641567A1 (en) | 1995-03-08 |
NZ264218A (en) | 1995-07-26 |
FI943705A0 (fi) | 1994-08-10 |
NO315843B1 (no) | 2003-11-03 |
AU679233B2 (en) | 1997-06-26 |
HU224613B1 (hu) | 2005-11-28 |
JP3745395B2 (ja) | 2006-02-15 |
NO942983L (no) | 1995-02-14 |
DK0641567T3 (da) | 2000-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY113806A (en) | Antiparasitic marcfortines and paraherquamides | |
ES2164731T3 (es) | Suspension acuosa tixotropica de agentes fitoprotectores. | |
EP0563345A4 (en) | Novel 4-arylpiperazines and 4-arylpiperidines | |
GR3035148T3 (en) | Retroviral protease inhibiting compounds. | |
GR3027657T3 (en) | N-alkylthio polyamine derivatives as radioprotective agents | |
TW249202B (da) | ||
GR3031781T3 (en) | Antifungal sordaridin derivatives | |
IN179094B (da) | ||
DE69818261D1 (en) | Hydroxycyclopentanone | |
DE69328900D1 (de) | Verfahren zur Reinigung von Teppichen | |
TW231256B (da) | ||
GB8913879D0 (en) | Hair treatment composition | |
EP0974347A4 (en) | ANTIVIRAL AGENTS | |
NZ279396A (en) | Octahydro-6-hetring[2,1-a][2]benzazepine disulphide derivatives | |
EP0978277A4 (en) | ANTI-RHUMATISMAL AGENTS | |
EP0978281A4 (en) | EYE DROPS | |
EP0994111A4 (en) | TETRAHYDROFURANNE DERIVATIVES | |
EP0659752A4 (da) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |